Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dermata Therapeutics Inc
(NQ:
DRMA
)
3.380
-0.098 (-2.83%)
Streaming Delayed Price
Updated: 3:53 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dermata Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Mid-Day Market Update: US Stocks Down; Nasdaq Falls 50 Points
February 07, 2022
Midway through trading Monday, the Dow traded down 0.10% to 35,053.40 while the NASDAQ fell 0.36% to 14,046.74. The S&P also fell, dropping, 0.26% to 4,488.93. Also check out this: Executives Sell Over...
Via
Benzinga
Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know
February 07, 2022
Dermata Therapeutics Inc (NASDAQ: DRMA) has requested the FDA to waive the requir
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 07, 2022
Gainers Enveric Biosciences (NASDAQ:ENVB) shares increased by 12.9% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $22....
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 02, 2022
Gainers Epizyme (NASDAQ:EPZM) stock increased by 14.2% to $1.41 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 9.6...
Via
Benzinga
51 Biggest Movers From Yesterday
January 26, 2022
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 24, 2022
Gainers Aptorum Group (NASDAQ:APM) stock m...
Via
Benzinga
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
January 13, 2022
SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
Dermata to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022
SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
54 Biggest Movers From Yesterday
December 08, 2021
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and...
Via
Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
December 07, 2021
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories....
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 23, 2021
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 157.46% to $5.69 during Tuesday's pre-market session. The company's market cap stands at $75.1...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 22, 2021
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of...
Via
Benzinga
50 Biggest Movers From Yesterday
November 30, 2021
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...
Via
Benzinga
Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why
November 19, 2021
Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 19, 2021
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares...
Via
Benzinga
68 Biggest Movers From Wednesday
November 26, 2021
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
November 19, 2021
- Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - Duration of effect lasted approximately 3 months - No potential distant spread of toxin observed SAN...
From
Dermata Therapeutics
Via
AccessWire
61 Biggest Movers From Yesterday
November 23, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...
Via
Benzinga
52 Biggest Movers From Friday
November 22, 2021
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second...
Via
Benzinga
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
November 17, 2021
- Topline results expected in second half of 2022 - Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021
- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -...
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
November 12, 2021
SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
November 11, 2021
SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 19, 2021
Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market session. The company's market cap stands at $...
Via
Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
October 19, 2021
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced...
Via
Benzinga
Dermata Stock Jumps On Positive Psoriasis Candidate Data
October 19, 2021
Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis. The percentage of treatment...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 18, 2021
Gainers Dermata Therapeutics (NASDAQ:DRMA
Via
Benzinga
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
October 18, 2021
- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 -...
From
Dermata Therapeutics
Via
AccessWire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.